Nirmatrelvir/Ritonavir : This section includes updated remarks for the existing recommendation on the use of nirmatrelvir/ritonavir for ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease.Anakinra : This section has been added and includes a new recommendation against the routine use of anakinra among hospitalized patients with severe COVID-19.Additionally, this section includes updated remarks for the existing recommendation on the use of convalescent plasma for ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease who have no other treatment options. Convalescent Plasma: A new recommendation was developed against the routine use of convalescent plasma among immunocompromised patients hospitalized with COVID-19.Version 11.0.0 has been released and includes the following: Mustafa,** Shahnaz Sultan,** Yngve Falck-Ytter** Morgan,** Amy Hirsch Shumaker, Lindsey Baden, Vincent Chi-Chung Cheng, Kathryn M. Medical Education Community of PracticeĪdarsh Bhimraj,* Rebecca L.Fellows-In-Training Career & Education Center.myIDSA Practice Managers Community Opt-in Form. Antimicrobial Stewardship Centers of Excellence Program.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |